TORONTO — The provincial government announced today that Ontario has confirmed its first case of the rare blood clot linked to the AstraZeneca vaccine. Dr David Williams, Ontario’s Chief Medical Officer of Health, said the following in a press release:
“We have confirmed the first case of the rare blood clotting condition known as vaccine-induced immune thrombotic thrombocytopenia (VITT) in Ontario. The patient is a male in his 60s who had received his first dose of the AstraZeneca/COVISHIELD vaccine. The patient has received treatment and is recovering at home. Additional details will not be publicly released to protect the patient’s privacy.”
Dr. Williams assures that, while blood clots remain extremely rare, the province is monitoring cases and is ready to respond should individuals develop symptoms. This case marks the fourth in Canada out of 1.1 million administered doses of the AstraZeneca vaccine.
“The Health Canada approved vaccines are the best way to protect your health and those around you. Ontarians are encouraged to get vaccinated as soon as they are eligible and monitor their health after receiving their vaccination.” He said.
Individuals who have received the AstraZeneca vaccine and develop the following symptoms are asked the call 9-1-1 immediately:
- Severe, persistent headache
- Blurred vision
- Shortness of breath
- Chest pain
- Leg swelling
- Persistent stomach/abdominal pain
- Unusual bruising or red/purple spots beyond the injection site where the vaccine was given
- Neurological symptoms such as weakness in the legs or seizures